CStone Pharmaceuticals (CStone Pharma) filed its Monthly Return for the period ended 31 March 2026, detailing only minor changes to its share capital structure.

The company’s authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001 each, representing total authorised capital of USD 0.20 million.

Issued share capital edged up by 3,349 shares during the month, lifting the total to 1.48 billion shares (1,476,018,722), while the issuer continued to hold zero treasury shares. The increase stemmed entirely from option exercises under the Post-IPO Employee Share Option Plan adopted on 30 January 2019 (last amended 7 March 2023).

Key option-related data: • Post-IPO Employee Share Option Plan – 3,349 options were exercised, reducing outstanding options to 105.94 million. • Pre-IPO Incentivization Plan – no movements; 1.18 million options remain outstanding. • Shares that may still be issued on full exercise of outstanding options stand at 27.87 million, with capacity for a further 21.72 million shares to be granted under the Post-IPO scheme.

Gross proceeds from March option exercises totalled HKD 0.01 million (HKD 6,067.35).

CStone Pharma confirmed compliance with the Hong Kong Stock Exchange’s minimum 25% public-float requirement as of 31 March 2026.